Comparison between [[sup.68]Ga]Ga-PSMA-617 and [[sup.18]F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma

The aim of this prospective clinical study was to evaluate the potential of the prostate specific membrane antigen (PSMA) targeting ligand, [[sup.68]Ga]-PSMA–Glu–NH–CO–NH–Lys-2-naphthyl-L-Ala-cyclohexane-DOTA ([[sup.68]Ga]Ga-PSMA-617) as a positron emission tomography (PET) imaging biomarker in recu...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-11, Vol.24 (22)
Main Authors: Brighi, Caterina, Puttick, Simon, Woods, Amanda, Keall, Paul, Tooney, Paul A, Waddington, David E. J, Sproule, Vicki, Rose, Stephen, Fay, Michael
Format: Article
Language:English
Subjects:
Biological products
Fay, Michael
Glioblastoma multiforme
PET imaging
Prostate cancer
Taxation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this prospective clinical study was to evaluate the potential of the prostate specific membrane antigen (PSMA) targeting ligand, [[sup.68]Ga]-PSMA–Glu–NH–CO–NH–Lys-2-naphthyl-L-Ala-cyclohexane-DOTA ([[sup.68]Ga]Ga-PSMA-617) as a positron emission tomography (PET) imaging biomarker in recurrent glioblastoma patients. Patients underwent [[sup.68]Ga]Ga-PSMA-617 and O-(2-[[sup.18]F]-fluoroethyl)-L-tyrosine ([[sup.18]F]FET) PET scans on two separate days. [[sup.68]Ga]Ga-PSMA-617 tumour selectivity was assessed by comparing tumour volume delineation and by assessing the intra-patient correlation between tumour uptake on [[sup.68]Ga]Ga-PSMA-617 and [[sup.18]F]FET PET images. [[sup.68]Ga]Ga-PSMA-617 tumour specificity was evaluated by comparing its tumour-to-brain ratio (TBR) with [[sup.18]F]FET TBR and its tumour volume with the magnetic resonance imaging (MRI) contrast-enhancing (CE) tumour volume. Ten patients were recruited in this study. [[sup.68]Ga]Ga-PSMA-617-avid tumour volume was larger than the [[sup.18]F]FET tumour volume (p = 0.063). There was a positive intra-patient correlation (median Pearson r = 0.51; p < 0.0001) between [[sup.68]Ga]Ga-PSMA-617 and [[sup.18]F]FET in the tumour volume. [[sup.68]Ga]Ga-PSMA-617 had significantly higher TBR (p = 0.002) than [[sup.18]F]FET. The [[sup.68]Ga]Ga-PSMA-617-avid tumour volume was larger than the CE tumour volume (p = 0.0039). Overall, accumulation of [[sup.68]Ga]-Ga-PSMA-617 beyond [[sup.18]F]FET-avid tumour regions suggests the presence of neoangiogenesis in tumour regions that are not overly metabolically active yet. Higher tumour specificity suggests that [[sup.68]Ga]-Ga-PSMA-617 could be a better imaging biomarker for recurrent tumour delineation and secondary treatment planning than [[sup.18]F]FET and CE MRI.
ISSN:1422-0067
1422-0067
DOI:10.3390/ijms242216208